## 1-Methoxyphaseollidin: A Promising Molecule for Research
1-Methoxyphaseollidin (1-MP) is a **natural compound** found in the **common bean** (Phaseolus vulgaris). It belongs to the **phaseollin family** of isoflavonoids, which are known for their diverse biological activities.
**Here's why 1-MP is important for research:**
* **Antioxidant properties:** 1-MP exhibits strong antioxidant activity, scavenging free radicals and protecting cells from oxidative stress. This could be beneficial for preventing or treating diseases like cancer and Alzheimer's.
* **Anti-inflammatory effects:** Studies have shown 1-MP to possess anti-inflammatory properties, potentially useful for managing inflammatory conditions like rheumatoid arthritis and inflammatory bowel disease.
* **Anti-proliferative activity:** 1-MP has demonstrated anti-proliferative effects on various cancer cell lines, suggesting its potential as a therapeutic agent for cancer treatment.
* **Neuroprotective properties:** 1-MP has shown promising neuroprotective effects, potentially protecting neurons from damage caused by oxidative stress and inflammation. This could be beneficial in treating neurological disorders like Parkinson's disease.
* **Anti-diabetic effects:** 1-MP has been shown to regulate blood sugar levels, suggesting its potential use in managing type 2 diabetes.
* **Other potential benefits:** 1-MP is also being investigated for its potential benefits in treating heart disease, osteoporosis, and skin conditions.
**However, it's important to note that:**
* While research on 1-MP is promising, **more studies are needed** to fully understand its mechanisms of action, potential benefits, and safety profile in humans.
* **Dosage and administration** of 1-MP still need to be optimized for therapeutic use.
**Overall, 1-methoxyphaseollidin is a fascinating molecule with a wide range of potential therapeutic applications. Its unique properties make it an intriguing subject for ongoing research, with hopes of developing new and effective treatments for various diseases.**
1-methoxyphaseollidin: a lysoPAF acetyltransferase inhibitor isolated from licorice root; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 480873 |
| CHEMBL ID | 1726462 |
| CHEBI ID | 175554 |
| MeSH ID | M0353045 |
| Synonym |
|---|
| (6ar,11ar)-1-methoxy-10-(3-methylbut-2-enyl)-6a,11a-dihydro-6h-[1]benzouro[3,2-c]chromene-3,9-diol |
| CHEBI:175554 |
| (6ar,11ar)-1-methoxy-10-(3-methylbut-2-enyl)-6a,11a-dihydro-6h-benzofuro[3,2-c]chromene-3,9-diol |
| (6ar,11ar)-1-methoxy-10-(3-methyl-but-2-enyl)-6a,11a-dihydro-6h-benzofuro[3,2-c][1]benzopyran-3,9-diol |
| 1-methoxyphaseollidin |
| smr000470936 |
| MLS000697598 |
| (6ar,11ar)-1-methoxy-10-(3-methylbut-2-enyl)-6a,11a-dihydro-6h-[1]benzofuro[3,2-c]chromene-3,9-diol |
| HMS2268P23 |
| CHEMBL1726462 |
| 65428-13-9 |
| FS-8832 |
| (6ar,11ar)-6a,11a-dihydro-1-methoxy-10-(3-methyl-2-buten-1-yl)-6h-benzofuro[3,2-c][1]benzopyran-3,9-diol |
| DTXSID601111460 |
| CS-0144780 |
| HY-N8489 |
| AKOS040760092 |
| (-)-1-methoxyphaseollidin |
| 6h-benzofuro[3,2-c][1]benzopyran-3,9-diol, 6a,11a-dihydro-1-methoxy-10-(3-methyl-2-butenyl)-, (6ar-cis)- |
| 52ZA5ZK5LU |
| 6h-benzofuro[3,2-c][1]benzopyran-3,9-diol, 6a,11a-dihydro-1-methoxy-10-(3-methyl-2-buten-1-yl)-, (6ar,11ar)- |
| Class | Description |
|---|---|
| pterocarpans | Members of the class of benzofurochromene with a 6a,11a-dihydro-6H-[1]benzofuro[3,2-c]chromene skeleton and its substituted derivatives. They generally bear structural resemblance to isoflavanoids that possess antibiotic activity and are produced by plant tissues in response to infection. They are the 3,4-dihydroderivatives of coumestans. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, JmjC domain-containing histone demethylation protein 3A | Homo sapiens (human) | Potency | 79.4328 | 0.6310 | 35.7641 | 100.0000 | AID504339 |
| glp-1 receptor, partial | Homo sapiens (human) | Potency | 31.6228 | 0.0184 | 6.8060 | 14.1254 | AID624417 |
| USP1 protein, partial | Homo sapiens (human) | Potency | 7.9433 | 0.0316 | 37.5844 | 354.8130 | AID743255 |
| TDP1 protein | Homo sapiens (human) | Potency | 20.7329 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
| Smad3 | Homo sapiens (human) | Potency | 10.0000 | 0.0052 | 7.8098 | 29.0929 | AID588855 |
| 67.9K protein | Vaccinia virus | Potency | 14.1254 | 0.0001 | 8.4406 | 100.0000 | AID720579 |
| DNA polymerase eta isoform 1 | Homo sapiens (human) | Potency | 89.1251 | 0.1000 | 28.9256 | 213.3130 | AID588591 |
| Rap guanine nucleotide exchange factor 4 | Homo sapiens (human) | Potency | 31.6228 | 3.9811 | 46.7448 | 112.2020 | AID720708 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| guanyl-nucleotide exchange factor activity | Rap guanine nucleotide exchange factor 4 | Homo sapiens (human) |
| protein binding | Rap guanine nucleotide exchange factor 4 | Homo sapiens (human) |
| cAMP binding | Rap guanine nucleotide exchange factor 4 | Homo sapiens (human) |
| protein-macromolecule adaptor activity | Rap guanine nucleotide exchange factor 4 | Homo sapiens (human) |
| small GTPase binding | Rap guanine nucleotide exchange factor 4 | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| cytosol | Rap guanine nucleotide exchange factor 4 | Homo sapiens (human) |
| plasma membrane | Rap guanine nucleotide exchange factor 4 | Homo sapiens (human) |
| membrane | Rap guanine nucleotide exchange factor 4 | Homo sapiens (human) |
| hippocampal mossy fiber to CA3 synapse | Rap guanine nucleotide exchange factor 4 | Homo sapiens (human) |
| plasma membrane | Rap guanine nucleotide exchange factor 4 | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1347086 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID1347083 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID1347082 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.72) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||